Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418730 | 0.92 | CYP2D6 (0.49) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL15470329 | 0.92 | CYP2D6 (0.49) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL20219409 | 0.90 | KCNH2 (0.47) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL15470397 | 0.90 | KCNH2 (0.47) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL20219312 | 0.89 | CYP2D6 (0.56) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13195751 | 0.89 | CYP2D6 (0.56) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL20219484 | 0.86 | KCNH2 (0.54) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL20386646 | 0.86 | KCNH2 (0.47) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL13195754 | 0.86 | KCNH2 (0.54) | KCNH2CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL23472386 | 0.85 | TLR8 (0.51) | KCNH2CYP2D6DRD1HTR2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | KCNH2 4679/4885CYP2D6 361/4885DRD1 3745/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885CYP2D6 361/4885DRD1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.